{
  "trial_id": "NCT04694079",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Acute Procedure endpoints Acute success will be defined as non-inducibility of any sustained monomorphic VT at the end of the procedure.",
      "label": "met"
    },
    {
      "criterion": "Device programming All patients involved in the study, regardless of Group allocation, will have their ICD programmed following 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on optimal ICD programming, following the manufacturer specific recommendations about therapy and detection in patients where VT cycle is known, alongside any anti-bradycardia setting necessary for therapeutic needs.",
      "label": "met"
    },
    {
      "criterion": "Medical therapy Patients involved in the study will be treated with antiarrhythmic drugs and any other medical therapy considered standard of care for the SHD and VT.",
      "label": "met"
    },
    {
      "criterion": "Potential benefits Thanks to preprocedural CMR imaging, patients assigned to both interventional groups (1 and could benefit from potentially shorter procedures and lower radiological exposure with shorter fluoroscopy time.",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "Withdrawal from the study Informed consent withdrawal",
      "label": "triggers"
    },
    {
      "criterion": "Statistics All applicable statistical tests will be 2-sided and will be performed using a 5% significance level.",
      "label": "unknown"
    }
  ],
  "notes": "Patient has history of CAD, MI, HLD, HTN, ventricular tachycardia, and syncope. He was recently discharged after a negative work-up for syncope which included the implantation of a cardiac monitoring device.",
  "_meta": {
    "topic_id": "19",
    "trial_id": "NCT04694079",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}